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Lineage or cell of origin of cancers is often unknown and thus is not a consideration in therapeutic approaches.
Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cancer for which the cell of origin remains
debated. We used conditional genetic mouse models of aRMS to activate the pathognomonic Pax3:Foxo1 fusion
oncogene and inactivate p53 in several stages of prenatal and postnatal muscle development. We reveal that
lineage of origin significantly influences tumor histomorphology and sensitivity to targeted therapeutics.
Furthermore, we uncovered differential transcriptional regulation of the Pax3:Foxo1 locus by tumor lineage of
origin, which led us to identify the histone deacetylase inhibitor entinostat as a pharmacological agent for the
potential conversion of Pax3:Foxo1-positive aRMS to a state akin to fusion-negative RMS through direct
transcriptional suppression of Pax3:Foxo1.
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Rhabdomyosarcoma is an aggressive solid tumor for which
the cell lineage of origin of alveolar rhabdomyosarcoma
(aRMS) remains debated (Tiffin et al. 2003; Charytonowicz
et al. 2009; Hettmer andWagers 2010;Hettmer et al. 2011).
Whereas the adult pleomorphic subtype is felt to originate
from muscle stem cells (satellite cells) (Hettmer et al.
2011; Blum et al. 2013), the embryonal subtype has been
attributed to arise more often from myoblasts than up-
streammyogenic progenitors (i.e., satellite cells), the latter
of which aremore prone to transform into undifferentiated
pleomorphic sarcomas (UPSs) having relatively little myo-
differentiation potential (Rubin et al. 2011). Even more
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intriguing are possible nonmyogenic cells of origin of
embryonal rhabdomyosarcoma (eRMS) from the adipo-
genic lineage (Hatley et al. 2012; Kikuchi and Keller 2012).
For the alveolar subtype that is often incurable when
metastatic (Malempati and Hawkins 2012; Hawkins
et al. 2013), we previously suggested Myf6-expressing
(differentiating) cells of the myogenic lineage as the cell
of origin (Keller et al. 2004a,b). These studies had used
conditional mouse models triggering in the Myf6Cre
lineage the pathognomonic Pax3:Foxo1 chimeric onco-
gene, which is commonly found in the human disease as
a result of a t(2;13) translocation (Arndt and Crist 1999).
Nevertheless, we and others have reconsidered whether
mesenchymal stem cells or satellite cells could be an
alternate cell of origin (Ren et al. 2008; Charytonowicz
et al. 2009; Hettmer and Wagers 2010), and thus we
performed the studies described here.
An interesting aspect of the search for cell of origin is that
we uncovered a differential susceptibility of the Pax3:Foxo1
locus to be transcribed based on the cell lineage originally
transformed. This finding may have translational signifi-
cance in that the related Pax7 locus inmyogenic progenitors
is a classic example of a bivalent epigenetic locus (Mozzetta
et al. 2011), with different transcriptional activation states
depending on degree ofmyodifferentiation, and thus is poten-
tially amenable to pharmacological intervention. Transcrip-
tion factors have not typically been considered approachable
therapeutic targets, but if transcription of Pax3:Foxo1 itself
could be inhibited, then the implicit conversion of fusion-
positive aRMS to fusion-negative RMS would have great
appeal, given the substantial difference in outcomes between
these two clinical groups in retrospective studies (Sorensen
et al. 2002; Missiaglia et al. 2012).
Results
The p53 pathway is frequently aberrant in aRMS
We and others have commonly used p53 inactivation in
mouse models of aRMS (Keller et al. 2004a), yet the
clinical relevance of p53 deregulation at the genetic
and/or functional pathway levels is debated (Takahashi
et al. 2004; Ognjanovic et al. 2012). To address this issue,
we usedmetagene analysis to test whether p53 functional
inactivation was a clinically relevant cooperative initiat-
ingmutation in aRMS (Supplemental Fig. S1A). Using our
previously described metagene analysis and S-score
method (Rubin et al. 2011), we analyzed a global gene
expression data set (Supplemental Tables 1, 2) of 62
PAX3:FOXO1+ and 24 PAX7:FOXO1+ human aRMS tumors
for aberrant signaling of the rhabdomyosarcoma-associated
p53 pathway. We found that 85% of PAX3:FOXO1+ tumors
exhibited a gene expression signature consistent with the
‘‘p53 off’’ state. Similarly, 75% of PAX7:FOXO1 tumors also
had a p53 off state. Thus, the p53 off state was a common
signature in human samples.
Pax3:Foxo1 leads to forms of sarcoma for satellite cells
different from any other myogenic lineage
Having established a prominent role for p53 pathway
inactivation and Pax3:Foxo1 activation as driver events
in the genesis of aRMS, we generated mouse models
(Keller et al. 2004a) to mimic these initiating driver
events through targeting to specific muscle cell types in
fetal and postnatal development (Fig. 1A). Tumors oc-
curred in embryonic muscle lineages (MCre for hypaxial
Pax3) and embryonic and fetal muscle lineages (Myf6Cre
for Myf6) as well as the postnatal satellite cell lineage
(Pax7CreER) (Fig. 1B,C). For the latter, tamoxifen was
administered at 30 d of age (adolescence). The Myf5Cre
lineage was embryonic-lethal (usually resulting in exen-
cephaly) (data not shown) in all litters except for one
animal (U24014) that later went on to develop a tumor of
the lower extremity at 74 d of age. The most susceptible
lineages were fetal myogenic progenitors and postnatal
satellite cells but not Myf5- or Myf6-expressing postnatal
committed myogenic progenitors: Of 18 Myf5CreER,
Pax3:Foxo1,p53 mice given tamoxifen at 30 d of life
(P30 [postnatal day 30]) and observed 43–510 d (median,
395), only one developed at age 401 d a tumor that was
diagnosed as aRMS solid variant of the cranial muscle
(Supplemental Fig. S1B–D). Similarly, fromeightMyf6CreER,
Pax3:Foxo1, p53 mice given tamoxifen at P30 and observed
232–505 d (median, 396), no mice developed tumors. Post-
natal lineage tracing of the postnatal Myf6CreER lineage
showed marking of myofibers as well as Pax7+ sublami-
nar satellite cells (Supplemental Fig. S2), a postnatal
result complementing a report that embryonic Myf6Cre
might prime Pax7+ satellite cells (Sambasivan et al. 2013).
However, despite a recent report showing thatMyf6Cre is
active in early embryonic muscle progenitors that can
become satellite cells (Sambasivan et al. 2013), other
evidence for theMyf6Cre fetal myoblast population being
a more common cell of origin for Pax3:Foxo1+ aRMS than
a postnatal satellite cell includes (1) the absence of
tumors fromMyf6CreER, Pax3:Foxo1, p53mice in which
Myf6+ satellite cells can activate Pax3:Foxo1, (2) the
absence of aRMS tumors from Pax7CreER, Pax3:Foxo1,
p53 mice in which the Pax7+ satellite cell population at
large can activate Pax3:Foxo1, and (3) the absence of
aRMS tumors from Myf5CreER, Pax3:Foxo1, p53 mice
whose nonquiescent satellite cells can activate Pax3:
Foxo1 (Biressi et al. 2013).
To address the reported possibility that nonmyogenic,
marrow-derived cells might give rise to aRMS—at least
when Pax3:Foxo1 is driven by a nonnative promoter (Ren
et al. 2008)—we first examined cells of the bone marrow
compartment for the presence of cells derived from
a Myf6Cre or Pax3CreKI (Pax3) (Engleka et al. 2005)
ontogeny using eYFP (Keller et al. 2004a) and RFP
(Vintersten et al. 2004) reporters, respectively. This line-
age tracing was done without introducing Pax3:Foxo1 or
p53 mutations. Neither the Pax3 nor the Myf6 lineage
was represented in the bone marrow compartment in
>0.4% of mesenchymal or hematopoietic cells (Supple-
mental Fig. S1E,F), and thus this line of experimentation
was discontinued.
At the histological level, the embryonic MCre (hypax-
ial Pax3Cre) and fetal Myf6Cre lineages led to aRMS
histology (Fig. 1D). The single animal that survived past
birth for the Myf5Cre lineage (U24014) also developed
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Figure 1. Characteristics of tumors from Pax7CreER, Myf5Cre,Myf6Cre, andMCremice. (A) Representation of prenatal and postnatal
myogenesis in the context of Cre drivers used to trigger tumors in this study. For Pax7CreER, Myf5CreER, and Myf6CreER mice,
tamoxifen was administered at P30 (see the Materials and Methods). (multinucl.) Multinucleated. (B) Pax7CreERmice andMCremice
showed prolonged survival and lower tumor incidence compared withMyf6Cre mice (tumor incidences were MCre, 40%; Pax7CreER,
38%; and Myf6Cre, 100% at 1 yr after birth). Myf5Cre mice were embryonic-lethal (see the text). All mice also harbor homozygous
Pax3P3Fm/P3Fm and p53F2-10/F2-10 alleles. (C) Location and disease stages in each strain. Pax7CreER tumors were more frequently
observed in head/neck and genital areas, whereasMCremice developed tumors exclusively in the extremities. The highest frequency of
stage IV metastasis (40%) was seen forMyf6Cremice. The IRSG staging system was scaled to mice such that a 4-mm-diameter mouse
tumor was equated with a 5-cm-diameter human tumor (Nishijo et al. 2009a). (D, top row) Histological analysis of tumors. Myf5Cre,
Myf6Cre, and MCre tumors were small round cells (aRMS), whereas most Pax7CreER tumors showed spindle cell morphology
(pleomorphic RMS/pleomorphic spindle cell sarcoma). (Bottom row) Immunohistochemistry for Myogenin. (E) eYFP protein expression
representing the transcriptional activation status of Pax3:Foxo1 fusion gene was at the lower limit of detection in Pax7-CreER tumors.
Bars, 10 mM.
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aRMS with numerous rhabdoid-type rhabdomyoblasts
and diffuse anaplasia (Fig. 1D). In contrast, the Pax7CreER
postnatal satellite cell lineage led to tumors diagnosed as
pleomorphic RMS/pleomorphic spindle cell sarcoma by
histological and immunohistochemical criteria (Fig. 1D).
Surprisingly, the eYFPmarker of Pax3:Foxo1was expressed
only weakly in Pax7CreER-derived tumors compared with
the other tumors (Fig. 1E). Correspondingly, Pax3:Foxo1
expression by RT–PCR was variable and generally low in
Pax7CreER tumors compared with mice bearing the
Pax3:Foxo1 conditional alleles and other Cre drivers
(Fig. 2A).
To begin exploring the potential causes of the low
Pax3:Foxo1 expression from Pax7CreER,Pax3,p53 tu-
mors, we evaluated the Cre/LoxP recombination effi-
ciency at the Pax3 locus. By genotyping tumors, Pax3
locus recombination frequency was found to be lower in
tumors of Pax7CreER-expressing satellite cell origin than
Myf6Cre-expressing prenatal (presumably myoblast) ori-
gin. Generally Pax7CreER tumors had only one Pax3
conditional knock-in allele, P3Fm, converted to the
active Pax3:Foxo1 form, P3Fa (Fig. 2B; see the Discus-
sion). In contrast, recombination for the p53 locus by
Pax7CreER in tumors was uniformly complete for both
p53 alleles. Furthermore, the lower Pax3 recombination
frequency alone would not account for the difference in
histology because Pax3 (P3Fa/WT) tumors from the
Myf6Cre lineage presented with an aRMS histology, not
a pleomorphic histology (Fig. 2C; Supplemental Table 3).
By quantitative analysis, the mean florescence intensity
of eYFP in primary tumor cell cultures derived from
Pax7CreER,Pax3(P3Fm/P3Fa) tumors was rarely above
the level of C2C12-negative control cells except in rare
instances (Fig. 2D; see the Discussion). On the other
hand, mean fluorescence intensity of eYFP in primary cell
cultures derived from aMyf6Cre,Pax3(P3Fa/P3Fa) tumor
was twofold to threefold higher than control C2C12 cells
(Fig. 2D). RT–PCR studies also showed higher levels of
Pax3:Foxo1 mRNA levels in murine primary tumor cell
cultures derived from Myf6Cre,Pax3(P3Fa/P3Fa) tumors
(Fig. 2E, green) compared with primary tumor cell cul-
tures from Pax7CreER,Pax3(P3Fa/P3Fa) tumors (U31425
and U28285) (Fig. 2E). Altogether, these results suggest
that inherently less transcription occurs from the Pax3
locus in Pax7CreER-derived tumors and decrease the
probability that aRMS arises from Pax7+ postnatal satel-
lite cells.
Tumors arising from non-Pax7CreER cell of origin
authentically recapitulate human aRMS
To further evaluate the lineages that might give rise to
aRMS, we compared expression of validated markers of
Pax:Foxo1+ aRMS and eRMS (Wachtel et al. 2006).Myf6Cre
myoblast-derived mouse tumors expressed significantly
higher levels of the Pax3:Foxo1-specific aRMS marker
Tcfap2b, whereas Pax7CreER satellite cell-derived tumors
expressed reciprocally higher levels of the eRMS-specific
marker Fbn2 (Fig. 3A). We then turned to principal compo-
nent analysis (PCA) to compare Pax3:Foxo1-bearing tumors
with those in the eRMS–UPS spectrum (Rubin et al. 2011).
Results showed that Pax7CreER satellite cell-derived tu-
mors were highly similar to eRMS/UPS tumor models that
we previously reported (Fig. 3B; Rubin et al. 2011). In
contrast, all Pax3:Foxo1-bearing tumors histologically con-
sistent with aRMS from the MCre (Pax3), Myf5Cre, and
Myf6Cre lineages formed an independent outgroup (Fig. 3B).
Thus, the Pax7CreER postnatal satellite cell lineage did not
appear to be poised for giving rise to aRMS when the
Pax3:Foxo1 oncogene at the Pax3 locus is triggered; instead,
cells of Pax7CreER satellite cell lineage had a tendency to
give a spindle cell-like tumor phenotype. We next hypoth-
esized that lineage-specific drug sensitivity could be best
interrogated by an ontogeny series that would include
Pax7CreER tumors for which Cre-mediated recombination
or transformation occurred after the satellite cell state.
From Figure 3B, we expected an intermediate state to be
rare, but from the Pax3:Foxo1 data in Figure 2E (i.e.,
samples U28285, U31423, and U29416), we expected at
least some instances to exist. To identify a potential ontog-
eny series, we first sought to find model primary cell
cultures best representing Pax3:Foxo1-harboring satellite
cell (Pax7CreER lineage)-derived tumors versus Pax3:
Foxo1-harboring myoblast (Myf6Cre lineage)-derived tu-
mors. Comparison of gene expression for these two tumor
types is given in Supplemental Table 4. The Pax7CreER
lineage was associated with expression of Cav1, Dcn, and
Cxcl12, whereas the Myf6Cre lineage was associated with
expression of Sct, Stc1, and Ryr3 (Supplemental Table 4).
We choose five primary cell cultures—i.e., U29415,
U31425, U28285, U31423, and U29416—of Pax7CreER
lineage and U20325, U23674, and U21459 of Myf6Cre
lineage to test the expression of Cav1, Dcn, Cxcl12, Sct,
Stc1, and Ryr3 by RT–PCR. These studies showed an
interesting gradient pattern in which the expression of
markers associated with Pax7CreER lineage was highest
in U29415 cells followed by U31425 or U28285 and lower
expression in Myf6Cre lineage primary cell cultures
U20325, U23674, and U21459. Conversely, the expression
of markers associated with Myf6Cre lineage showed a re-
verse gradient pattern where the highest expression was
observed in U21459/U23674, followed by U29416 or
U20325, U31423, U28285, U31425, and U29415 cells
(Supplemental Fig. S3A). These results suggested that
U31425, U28285, U31423, and U29416 represent the ‘‘in-
termediate’’myodifferentiation and transformation between
U29415 (Pax7CreER) and U23674/U21459 (Myf6Cre) (Sup-
plemental Fig. S3A). Having this ontogeny series in hand,we
sought to test the therapeutic significance of the difference
in cell of origin by subjecting the ontogeny series of primary
cell cultures to cell cycle-specific inhibitors that we rea-
soned from the literature (Jahn et al. 1994; De Falco and De
Luca 2006) may have differential sensitivity to cells of
increasing myodifferentiation. The four cell cultures did
indeed have differential sensitivities to the Cdk-2, Cdk-8,
and Cdk-9 inhibitor SNS-032 and the Cdk-4/6 inhibitor
PD0332991 (Fig. 3C,D). The primary tumor cell culture
U23674 (Myf6Cre myoblast origin) was found to be the
most sensitive to SNS-032 and PD0332991 compared with
the other three primary tumor cell cultures (Pax7CreER
Alveolar rhabdomyosarcoma cell of origin
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satellite cell lineage), suggesting that the cell of origin of
the sarcoma might play a role in deciding the treatment
strategy for patients. Similar results were observed for the
FGFR1–4 inhibitor, LY287445, and Wee1 inhibitor, MK-
1775, whereby Myf6Cre lineage-derived U23674 was
found to be the most sensitive to these two drugs
compared with intermediate ontogeny cultures U29416
and U31423 and Pax7CreER satellite cell lineage-derived
U29415 (Supplemental Fig. S3C,D). Interestingly, when
Pax3:Foxo1 was stably knocked down in U23674 cells
Figure 2. Recombination status of Pax3 allele differs by cell of origin. (A) Relative expression of Pax3:Foxo1 in mouse tumor tissue. (B)
Genotyping for Pax3:Foxo1 and p53 recombination by cell of origin (Cre driver). Satellite cell-derived (Pax7CreER) primary tumor cell
cultures showed reduced efficiency in the recombination of Pax3:Foxo1 knock-in allele locus compared with myoblast-derived primary
tumor cell cultures (Myf6Cre). However, p53 locus conditional alleles were uniformly inactivated in all tumors irrespective of Cre
driver. (C) Representative H&E staining of tumors with Cre driver and Pax3 locus genotypes as noted. All tumors had homozygous
conditional p53 deletion.Myf6Cre lineage tumors with heterozygous or homozygous activation of Pax3:Foxo1 showed small round cell
histology consistent with aRMS. In contrast, Pax7CreER tumors with heterozygous or homozygous activation of Pax3:Foxo1 exhibited
pleomorphic spindle cell appearances, similar to tumors with only p53 inactivation—neither of which appearance is consistent with
aRMS. (D) Flow cytometry of eYFP for Pax7CreER- and Myf6Cre-derived primary tumor cell cultures. The mean florescence intensity
was lower in Pax7CreER rhabdomyosarcoma cells, although select tumors of the Pax7CreER lineage (e.g., U31423 and U29416) more
resembled Myf6Cre in eYFP expression (see the Results). (E) Quantitative RT–PCR (qRT–PCR) studies showing higher levels of
Pax3:Foxo1 mRNA levels in Myf6Cre-derived primary tumor cell cultures (U23674 and U57844) compared with Pax7CreER-derived
primary tumor cell cultures (U29415, U31425, and U31423). Statistically significant difference in Pax3:Foxo1 expression was observed
between Myf6Cre- and Pax7CreER-derived primary tumor cell cultures with one activated Pax3:Foxo1(P3Fa) allele (U57844 and
U29415) versus primary tumor cultures with two activated Pax3:Foxo1 alleles (U23674 and U31425).
Abraham et al.
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(U23674 ShY08), there was no difference in their sensi-
tivity to either SNS-032 (Fig. 3E) or PD0332991 (Fig. 3F)
compared with the control cells (U23674 ShC01), further
supporting that differential drug sensitivitywas due to lineage
of origin (i.e., epigenetic memory) and not Pax3:Foxo1
expression level.
The Pax7 and Pax3:Foxo1 loci are epigenetically
regulated (differential effects of epigenetic modifiers
on Pax3:Foxo1 and Pax7 expression depending
on the tumor cell of origin)
We next reasoned that if tumor initiation and tumor
phenotype is epigenetically determined, then the tumor
phenotype can be epigenetically modified by pharmaco-
logical agents. The Pax7 locus in activated satellite cells
has a bivalent chromatin domain with the presence of
both positive (H3K4me3) and negative (H3K27me3) his-
tone marks (Mozzetta et al. 2011), and we hypothesized
that the Pax3 locus may be similar. To gain insight into
the epigenetic regulation of the Pax3:Foxo1 locus, we
examined active (H3K4me3 and H3K9Ac) and repressive
(H3K27me3 and H3K9me3) histone modification marks
by chromatin immunoprecipitation (ChIP) in tumor cells
representing both Pax7CreER (U29415 and U31425) and
Myf6Cre (U23674 and U21459) lineages of origin. For this
study, we analyzed two genomic regions upstream (193:
285) of and downstream (+593: +462) from the transcrip-
Figure 3. Pax3:Foxo1 and aRMS-specific marker
expression in Pax3:Foxo1 tumors. (A) For tumors
bearing conditional Pax3:Foxo1 alleles, expression of
aRMS-specific classifier Tcfap2b was significantly
increased in Myf6Cre-derived tumors (M6-P3F-p53)
and comparatively lower in Pax7CreER-derived tu-
mors (P7er-P3F-p53); conversely, expression of eRMS-
specific marker Fibrillin2 (Fbn2) was increased in
Pax7CreER-derived, Pax3:Foxo1-bearing tumors and
comparable with the level of Fbn2 from eRMS de-
rived from satellite cells (P7er-Ptch1-p53) or myo-
blasts (M6-p53). (B) PCA showing the non-satellite
cell-derived, Pax3:Foxo1-bearing tumors as an out-
group and Pax7CreER-derived, Pax3:Foxo1-bearing
tumors grouping with spindle cell sarcoma/eRMS
tumors bearing Ptch1 and p53 mutations. (C,D) Cell
viability assay showing differential drug response of
primary tumor cell cultures along the continuum of
satellite cell-derived (Pax7CreER) origin versus myo-
blast-derived (Myf6Cre). (C) For the Cdk-2, Cdk-7,
and Cdk-9 inhibitor SNS-032, the IC50 values were
0.24 mM for U23674, 0.83 mM for U29415, 1.79 mM
for U31423, and 2.61 mM for U29415. (D) For the
Cdk-4,-6 inhibitor PD0332991, the IC50 values were
2.69 mM for U23674, 3.61 mM for U29415, 4.77 mM for
U31423, and 8.15 mM for U29415. (E,F) Cell viability
assay showing no difference in the response of
U23674 ShY08 cells (Pax3:Foxo1 stable knockdown
cells) to SNS-032 (E) and PD0332991 (F) compared
with the control knockdown cells, U23674 ShC01.
For SNS-032, the IC50 values were 0.1305 mM for
ShC01 cells and 0.1730 mM for ShY08 cells. In the
case of PD0332991, the IC50 values were 6.90 mM for
ShC01 cells and 6.88 mM for ShY08 cells. (s.c.)
Satellite cell origin; (m.b.) myoblast origin.
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tional start site (TSS) of the Pax3 locus. At the level of
histone marks, we observed a different chromatin state of
the Pax3:Foxo1 locus in primary tumor cell cultures with
different lineages of origin. As shown in Supplemental
Figure S4, higher levels of both H3K4me3 and H3K9Ac
active chromatin marks are observed in U23674 and
U21459 cells compared with U29415 and U31425 tumor
cells, correlating with high versus low Pax3:Foxo1 ex-
pression, respectively. Also high levels of repressive
histone marks H3K27me3 and H3K9me3 were observed
in U29415 and U31425 cells compared with U23674 and
U21459 cells. Altogether, these data suggest that the
observed differences in Pax3:Foxo1 mRNA levels could
be explained by a different chromatin state in these loci
depending on the tumor lineage of origin. From the RT–
PCR studies described above, U29415 was selected as
a representative Pax7CreER lineage tumor culture, and
U23674 was selected as a representativeMyf6Cre lineage
tumor culture.
To determine whether the Pax locus could be pharma-
cologically modified, we first treated murine primary
tumor cell cultures U23674 and U29415 with varying
doses of 5-Aza 29deoxycytidine (DNA methyltransferase
inhibitor) or SAHA and entinostat (histone deacetylase
[HDAC] inhibitors) to determine a sublethal dose at
which cells could be treated to study the effects of these
drugs on expression of Pax3:Foxo1 and Pax7 (Supplemen-
tal Fig. S5). Cells were treated with drugs for 72 h, after
which an MTS assay was performed to assess viability.
Based on these studies, U23674 cells were treated with
3 mM5-Aza-29deoxycytidine, 2 mM entinostat, or 0.75 mM
SAHA for 24 h, after which RNA was extracted, and the
expression of Pax3:Foxo1 and Pax7was examined by RT–
PCR. For U23674 tumor cells of the Myf6Cre myoblast
lineage, a decrease in both Pax7 and Pax3:Foxo1 mRNA
levels upon treatment with all of the drugs was observed,
but the effect was more pronounced for HDAC inhibitors
(Fig. 4A). Interestingly, U29415 tumor cells of Pax7CreER
satellite cell lineage showed a paradoxical increase in
mRNA levels of Pax7 and Pax3:Foxo1 when treated with
20 mM 5-Aza-29deoxycytidine, 15 mM entinostat, and
5 mM SAHA (Fig. 4A). As expected, the rare tumor cul-
tures downstream from U29415 behaved similarly to
the Myf6Cre tumor cultures (Supplemental Fig. S6). We
next determined epigenetic marks of Pax3:Foxo1 by per-
forming ChIP and examining the active histone marks
H3K4me3 and H3K9Ac along with the repressive marks
H3K27me3 and H3K9me3 previously examined in Sup-
plemental Figure S4. However, examination of these
specific chromatin marks did not explain the change in
Pax3:Foxo1 transcript levels, implying that other re-
gions may be the targets of chromatin remodeling for
entinostat.
Previous studies in mdx mice treated with a TNF-a
antibody reported increased levels of Pax7 mRNA in
satellite cells derived from myofibers (Palacios et al.
2010). TNF-a has been shown to activate p38a kinase,
which leads to interaction between YY1 and PRC2
(polycomb-repressive complex 2) via threonine phosphor-
ylation of EZH2. These proteins together form a repres-
sive complex at the Pax7 promoter and thus regulate the
expression of Pax7 (Palacios et al. 2010). To investigate
whether TNF-a can regulate the expression of Pax7 in
U23674 and U29415 tumor cells, cultures were treated
with 10 ng/mL recombinant TNF-a for 24 h. RT–PCR data
showed a reduction in mRNA levels of Pax7 in both
U23674 andU29415 cells. TNF-a also reduced Pax3:Foxo1
levels in both cell cultures (Fig. 4A). We next examined
the levels of Pax3:Foxo1 at the protein level. By immu-
noblotting, concomitant reduction in Pax3:Foxo1 levels
in U23674 cells treated with 2 mM entinostat for 24 h was
observed (Fig. 4B). This effect was seen across species for
human aRMS cell lines Rh30 (24 h of treatment) and
Rh41 (24 h of treatment) (Fig. 4C,D). When murine and
human tumor cultures were treated with 2 mM entinostat
for 72 h, a pronounced reduction in Pax3:Foxo1 protein
levels was observed (Fig. 4E,F). These results showed in
principle that Pax3:Foxo1 and Pax7 transcription and
protein levels can be modified pharmacologically. To
investigate whether the reduction in Pax3:Foxo1 protein
levels upon entinostat treatment is mediated by changes
in post-translational stability attributable to direct HDAC–
Pax3:Foxo1 interactions, we treated human and murine
aRMS cultures (Rh41 for 24 h and U23674 for 72 h) with 2
mM entinostat alone or in combination with MG132
(proteasome inhibitor). No increase in Pax3:Foxo1 pro-
tein level was observed when cells were treated with
a combination of entinostat and MG132 compared with
cells treated with entinostat alone (Fig. 4G,H). This
result suggests that the reduction in Pax3:Foxo1 levels
observed upon entinostat treatment is mediated at the
transcriptional (or post-transcriptional) level and not at
the post-translational level. Other studies from our
laboratory have shown that expression of Pax3:Foxo1
is G2 cell cycle phase-dependent (Kikuchi et al. 2014).
To investigate whether the reduction in Pax3:Foxo1
expression caused by entinostat treatment is cell cy-
cle-dependent, we performed a series of studies suggest-
ing that this was not necessarily the case (Supplemental
Fig. S7).
Entinostat slows tumor growth in vivo
We next tested the anti-tumor efficacy of entinostat in an
orthotopic allograft model of rhabdomyosarcoma gener-
ated by injecting U23674 cells into the cardiotoxin-
preinjured gastrocnemius muscle in the right leg of
SCID-hairless (SHO-Prkdcscid Hrhr) mice. Once the tu-
mors reached 0.25 cm3, themice were treated with a daily
dose of 10 mg/kg entinostat by intraperitoneal injection,
with 0.25 mg/kg actinomycin D by intraperitoneal in-
jection on day 1 of treatment, a combination of entinostat
and actinomycin D, or vehicle (DMSO) (Fig. 5A,B).
Actinomycin D is one of the commonly used chemother-
apeutic agents for treating rhabdomyosarcoma. The tu-
mors in the entinostat cohort grew significantly slower
than either vehicle- or actinomycin D-treated mice (P =
0.03). Mice treated with a combination of entinostat and
actinomycin D had a significantly slower rate of tumor
growth, and their tumors took more time to reach 1 cm3
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Figure 4. Pharmacologically modified epigenetic regulation of Pax3:Foxo1. (A) RT–PCR assays showing relative expression of
Pax3:Foxo1 and Pax7 in representative satellite cell-derived U29415 and myoblast-derived U23674 murine primary tumor cell cultures
upon treatment with DMSO, 5-Aza-29deoxycytidine (Aza), SAHA, entinostat (Ent), serum-free medium (SFM), and the cytokine TNF-a
(10 ng/mL in serum-free medium) for 24 h. The U29415 primary tumor cell culture (satellite cell origin) showed an increase in Pax7 and
Pax3:Foxo1 expression upon treatment with 5-Aza-29deoxycytidine, SAHA, and entinostat for 24 h, whereas the U23674 primary
tumor cell culture (myoblast origin) showed a decrease in the mRNA levels of Pax7 and Pax3:Foxo1 upon treatment. However,
treatment with TNF-a showed a reduction in the expression of Pax7 and Pax3:Foxo1 in both U29415 and U23674 cells. (B) Immunoblot
showing reduction in Pax3:Foxo1 levels upon treatment with 2 mM entinostat (Ent) and also with 3 mM 5-Aza-29deoxycytidine (Aza) for
24 h in U23674 cells. (C) Reduction in Pax3:Foxo1 level upon treatment with 2 mM entinostat (Ent) for 24 h in Rh30 cells. (D) Western
blot showing reduction in Pax3:Foxo1 levels upon treatment with 2 mM entinostat (Ent) for 24 h in Rh41 cells. (E) Immunoblot showing
significant reduction in Pax3:Foxo1 levels upon treatment with 2 mM entinostat (Ent) for 72 h in U23674 cells (left panel) and the
graphical representation (right panel). (F) Immunoblot showing a significant reduction in Pax3:Foxo1 level upon treatment with 2 mM
entinostat (Ent) for 72 h in Rh30 cells (left panel) and the graphical representation for this blot (right panel). (G) Western blots showing
no increase in Pax3:Foxo1 levels in Rh41 cells when they were treated with a combination of the proteasome inhibitor MG132 (0.1 mM,
0.5 mM, and 1 mM) and 2 mM entinostat for 24 h compared with cells treated with entinostat alone. Expression of Noxa was observed
when cells were treated with a combination of MG132 and entinostat in Rh41 cells. (H) Western blot showing no increase in
Pax3:Foxo1 levels in U23674 cells even when these cells were treated with a combination of 200 nMMG132 and 2 mM entinostat for 72 h
compared with cells treated with 2 mM entinostat alone. Noxa could not be detected even after treating the cells with a combination of
MG132 and entinostat for 72 h.
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in size compared with vehicle-treated or actinomycin
D alone-treated mice (P < 0.001) (Fig. 5 A,B). However,
after 5 d of treatment with entinostat, the mice showed
symptoms of drug toxicity (>10% loss of body weight),
and hence no treatment was administered on day 6, and
the subsequent daily dose of entinostat was reduced to
5 mg/kg.
Discussion
In our studies, we sought to refine experimentally the
range of possibilities for the cell of origin of Pax3:Foxo1+
rhabdomyosarcoma. Parenthetically, however, the cell of
origin for Pax7:Foxo1+ aRMS is in no way addressed in
this study. Surprisingly, in our experiments, the fetal
myoblast (Myf6 lineage) appears most susceptible to
formation of metastatic aRMS. In contrast, muscle stem
cells (satellite cells) appear least poised to give rise to
rhabdomyosarcoma—at least from adolescence onward.
With regard to tumor initiation, our data suggest that the
Pax3 chromatin structure may be closed (and relatively
inaccessible to events like Cre/LoxP DNA recombina-
tion) and show that transcription from the Pax3 locus is
inactive in tumor cells of this satellite cell lineage.
However, this low transcriptional activity could be re-
versed by pharmacological epigenetic modifiers. Even
more importantly, Pax3:Foxo1 can be reduced at the
mRNA and protein level in myoblast-derived tumors by
the same pharmacological epigenetic modifiers. The
implication that cell of origin can influence pharmaco-
logical response is interesting, if not provocative. We
concede, however, that common drug sensitivities are
likely also found between tumors of different origins and
that while some cell biological properties that may be
transmitted from the cell of origin, as many or more may
be the result of convergent, facultative phenotypes for
tumor cell growth—even if rhabdomyosarcomas arise
from different cell lineages.
What is remarkable is that a prenatal (Myf6Cre) lineage
of origin should, in our comparison, be most capable of
forming aRMS (at least in the context of p53 loss of
function). Rhabdomyosarcoma is a disease that has a
steady incidence throughout childhood (aRMS contrasts
dramatically with eRMS, the latter of which peaks with
toddler and adolescent growth spurts) (Ognjanovic et al.
2009). Suggestion of Myf6+ prenatal or postnatal myo-
genic cells, possibly a terminally differentiating subpop-
ulation, as an aRMS cell of origin was first reported by our
group (Keller et al. 2004a,b) and later complemented by in
vitro studies of human postnatal myoblasts transformed
by PAX3:FOXO1 and other cooperative initiating muta-
tions (Naini et al. 2008). Congenital fusion-positive aRMS
is rarely reported, and congenital aRMS is generally
fusion-negative (Godambe and Rawal 2000; Grundy et al.
2001; Sueters et al. 2005), although the PAX3:FOXO1
translocation has been detected in rare neonatal instances
(Rodriguez-Galindo et al. 2001). What might account for
the delay? One explanation might be an accumulation of
other genetic changes (mutations), but epigenetic changes
during childhood and adolescent growth and development
might also have a role to play. In fact, epigenetic abnor-
malities are very common in human cancers—and, in
contrast to genetic mutations, these epigenetic changes
are potentially reversible.
Can cells other than those of skeletal muscle lineages
give rise to aRMS? We are increasingly intrigued by this
possibility, although the question needs to be addressed
with prudence. A mesenchymal stem cell origin for
aRMS has been suggested (Charytonowicz et al. 2009;
Hettmer and Wagers 2010). In support of this possibility,
Figure 5. Anti-tumor activity of entinostat in an orthotopic allograft mouse mouse model of rhabdomyosarcoma. (A) Tumor-bearing
mice were treated with entinostat (dotted black line; n = 9; 10 mg/kg daily by intraperitoneal route), actinomycin D (black line; n = 8;
0.25 mg/kg on day 1 of treatment by intraperitoneal route), entinostat + actinomycin D (gray line; n = 8), and DMSO (dotted gray line;
n = 7). The graphs shows mean tumor size 6 SE by treatment and time. Tumor size increased monotonically with time after treatment
with actinomycin D, DMSO, and entinostat and exhibited a downward trend after day 8 for the treatment group with actinomycin D +
entinostat. The black arrows indicate the days on which entinostat- or entinostat + actinomycin D-treated mice were sacrificed for
10%–15% body weight loss. (B) Kaplan-Meier survival curves for tumor-bearing mice treated with entinostat daily, actinomycin D on
day 1, entinostat + actinomycin D, and vehicle (DMSO), with endpoint measurement being the number of days taken for the tumor to
reach 1 cm3 in size. A null hypothesis that the treatment-specific survival curves are equal was tested using a log-rank test and
concluded that the four curves are significantly different (P < 0.001).
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clinical cases of metastatic tumors without primary
tumors have been reported for t(1;13) PAX7:FOXO1
aRMS (Lisboa et al. 2008) and t(2;13) PAX3:FOXO1 aRMS
(Sandberg et al. 2001; Lisboa et al. 2008). An experimental
study by Ren et al. (2008) tested the possibility that
constitutively expressed (ectopic) Pax3:Foxo1 could cre-
ate aRMS, but this study did not place Pax3:Foxo1 under
the authentic control of the Pax3 promoter, which, in
light of our studies of a very small (0.4%) bone marrow
compartment cell population that had ever expressed
Pax3, makes the probability of aRMS arising from mes-
enchymal stem cells very low. However, a nonmarrow
mesenchymal stem cell of origin remains possible.
An interesting alternative cell of origin for aRMS is the
pericyte or mesangioblast. Vascular mimicry in rhabdo-
myosarcoma suggests a plasticity that may (or may not)
have carried over from an angioblast origin (Sun et al.
2004). An interesting case of primary rhabdomyosarcoma
of the pulmonary artery was also recently reported
(Suman et al. 2013). Experimentally, Lagha et al. (2009)
reported that in the mouse embryonic dermamyotome,
the ratio of Pax3 to Foxc2 balances fate between myo-
genic and vascular cell fates but that Pax3:Foxo1 sup-
presses Foxc2. This latter result suggests that, in the
susceptible cell, an angiogenic precursor might be con-
verted to a myogenic state, a result that has been shown
experimentally for embryonic aortic mesangioblasts
(Messina et al. 2009). The link between vascular pre-
cursors and the Pax3 lineage does not come as a surprise
given the known role of Pax3 in the migration of cardiac
neural crest during embryogenesis (Conway et al. 1997).
In a provocative study, Goupille et al. (2011) have shown
that smooth muscle cells of arteries express Pax3 and are
able to contribute to skeletal muscle fiber formation via
in vitro coculture conditions and following cell–cell
fusion. This plasticity lends itself to the possibility that
mesangioblasts or even smooth muscle cells can trans-
form into myogenic phenotype cancers (rhabdomyosar-
comas) under select conditions.
Our results raise a potentially important clinical im-
plication by suggesting that PAX3:FOXO1 levels vary by
cell of origin, even adjusting for recombination frequency;
thus, PAX3:FOXO1 RT–PCR alone may be less sensitive
than cytogenetics or FISH to detect the PAX3:FOXO1
rearrangements. Could someMFH or UPS cases be in fact
a spindle cell variant of aRMS, arising from satellite cells?
Pathologists might consider addressing this possibility in
cases of pediatric and adolescent undifferentiated sarco-
mas and consider FISH for PAX3:FOXO1 in atypical
cases.
Translationally, our data suggest a mechanism by
which fusion-positive aRMS might be epigenetically
reprogrammed into fusion-negative RMS using the adult
phase II HDAC inhibitor entinostat. Transcription factors
were once considered undruggable, but our approach
complements other experimental demonstrations for
EWS:FLI1 in pediatric Ewing’s sarcoma (Barber-Rotenberg
et al. 2012) and MLL-associated pediatric leukemias
(Chen et al. 2013). While additional preclinical studies
remain to be done, it is exciting to consider that entinostat
might reduce PAX3:FOXO1 levels sufficiently to convert
fusion-positive RMS with a poor prognosis to a biolog-
ical state akin to fusion-negative RMS, which portends
a significantly better prognosis even when metastatic
(Sorensen et al. 2002; Missiaglia et al. 2012).
Materials and methods
Microarray analysis for S scores and PCA
Humanmicroarray data sets were previously published (Wachtel
et al. 2004; Lae et al. 2007; Davicioni et al. 2009). Patient
demographics are presented in Supplemental Table 1, A and
B. Metagene and S-score analyses were conducted as previously
described (Rubin et al. 2011). For mouse tumors, gene expression
analysis was performed using Illumina’s Mouse Ref 8 Beadchip
version 1 (Illumina, Inc.). These data sets have been deposited in
Gene Expression Omnibus as accession entry GSE22520 and are
also described in Supplemental Table 1C. Rank invariant nor-
malization was performed on the log2 transformed expression
value. Afterward, we applied PCA to all mouse tissue samples
with the 19,070 probes (selected with the criterion of average
log2 intensity >5.5 and standard deviation >0.1) and then plotted
in three-dimensional space for visualization (Fig. 4B). Similar
microarray data analysis and the PCA methods were previously
described (Rubin et al. 2011). All bioinformatics tasks were
performed with MATLAB/Bioinformatics Toolbox (MathWorks,
Inc.) unless otherwise noted.
We downloaded the public domain data sets for fusion-
negative RMS reported by Davicioni et al. (2006) from https://
array.nci.nih.gov/caarray/project/details.actionproject.experiment.
publicIdentifier=trich-00099 as well as aRMS rhabdomyosar-
coma data sets from previously published reports (Wachtel
et al. 2004; Lae et al. 2007). These fusion-negative RMS and
aRMS data sets were designated as the test samples, whereas
normal skeletal muscle samples reported by Bakay et al. (2002)
were used as the control group. We also downloaded signature-
specific data sets as described below. All of the studies were
performed on an Affymetrix U133A array platform (Affymetrix).
Sample IDs used are given in Supplemental Tables 1 and 2.
Control samples of each examination are the eRMS samples
derived from Rubin et al. (2011). We selected 10 high positive, 10
low positive, and 10 negative control samples for each examina-
tion, whereas gene-wise t-tests were performed between the 20
positive controls and normal skeletal muscle in order to apply to
S score. S score is a subtype scoring method to quantify each
sample’s consistency. By using the S score, we can unambigu-
ously identify sample status and the amplitude of pathways or
biological processes that gene signatures have depicted. The
detailed S-score method has been previously described (Rubin
et al. 2011).
We used previously established gene lists (Rubin et al. 2011) to
examine whether human fusion-negative RMS and aRMS tu-
mors had evidence of p53 loss of function, Shh gain of function,
pRb loss of function, or Ras activation. Gene signatures of p53
loss of function were derived from gene expression data sets in
breast cancer (Miller et al. 2005). We also downloaded data sets
for medulloblastoma samples known to exhibit a Shh gain-of-
function signature (Thompson et al. 2006). We took homolog
genes from Rb1 wild-type and homozygous Rb1-deleted fusion-
negative mouse sarcomas to be pRb loss-of-function gene signa-
ture (Rubin et al. 2011). For Ras activation, we used gene lists for
the activated Ras signature of zebrafish eRMS (Langenau et al.
2007). The details of obtaining gene signature of each case have
been previously described (Rubin et al. 2011).
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Mice
All animal procedures were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Texas Health Science Center at San
Antonio or Oregon Health and Science University. TheMyf6Cre,
Myf5Cre, Pax7Cre, MCre, Pax7CreER, Pax3:Foxo1, LUSEAP,
LacZ reporter (Rosa26tm1Sor), Pax3-Cre (Pax3CreKI), and condi-
tional p53 mouse lines and corresponding genotyping protocols
have been described previously (Soriano 1999;Marino et al. 2000;
Jonkers et al. 2001; Keller et al. 2004a; Brown et al. 2005; Nishijo
et al. 2009a,b). Myf5CreER have been reported (Biressi et al.
2013), andMyf6CreERmice will be reported in detail elsewhere
but are also described in Supplemental Figure S2. For Pax7CreER,
Myf5CreER, and Myf6CreER mice, tamoxifen was administered
at P30 as previously reported (Keller et al. 2004a). Tumor-prone
mice were visually inspected every 2 d for tumors because of the
fulminant onset in these models. Genotyping protocols for
Pax3:Foxo1 and p53 were performed as described (Keller et al.
2004a).
Mouse primary tumor cell cultures
Mouse primary tumor cell cultures were generated from mouse
tumors as described previously (Abraham et al. 2011).
Survival analysis and statistical methods
Kaplan-Meier survival analysis of the mice was performed with
the endpoint being the development of tumors (i.e., disease-free
survival). Survival plots were created using the survival package
in R. Relative expression of Pax3:Foxo1 values were compared
using the Mann-Whitney test (Fig. 2A). The log-rank test (Fig.
3A) was used to determine the statistical significance (P < 0.05)
using Systat12 software (Systat Software, Inc.). The expression of
Pax7 and Pax3:Foxo1 compared with corresponding reference
groups was done using theMann-Whitney test with the Hochberg
correction for multiple testing (Fig. 4A). Statistical analyses were
performed using R 3.0.1 (The R Foundation for Statistical Com-
puting, http://www.r-project.org).
RNA isolation and quantitative RT–PCR (qRT–PCR)
RNA isolation and RT–PCR frommouse tumors were performed
as previously described (Nishijo et al. 2009a; Rubin et al. 2011).
Probe sets for mouse samples were Gapdh-Mm99999915_g1,
Fbn2_Mm00515742_m1, and Tcfap2b_Mm00493468_m1. Sta-
tistical analysis was performed by Kruskal-Wallis test with
Tukey’s multiple testing correction. For drug treatment studies,
the myoblast-derived primary tumor cell culture U23674 was
treated with either 750 nM SAHA, 3 mM 5-Aza-29deoxycytidine,
or 2 mM entinostat, and the satellite cell-derived primary tumor
cell culture U29415 was treated with either 5 mM SAHA, 20 mM
5-Aza-29deoxycytidine, or 15 mM entinostat for 24 h. After drug
treatment, total RNA was isolated, and cDNA was synthesized
as described above. The expression of Pax3:Foxo1 and Pax7 was
determined by qRT–PCR using TaqMan primers and probes
(mouse Pax7-Mm00834032_m1) on a StepOnePlus real-time
PCR system from Applied Biosystems.
Histology, immunohistochemistry, and immunochemistry
For MyoD, Myogenin, and Desmin immunohistochemistry,
staining was performed as previously described (Rubin et al.
2011). Immunofluorescence for GFP has also been described
previously (Nishijo et al. 2009a). For immunocytochemistry,
murine rhabdomyosarcoma primary tumor cell cultures (U23674)
and human rhabdomyosarcoma cell lines (Rh41) were cultured
in an eight-well CultureSlide (BD Falcon). The cells were washed
with PBS, fixed with 4% paraformaldehyde, permeabilized with
0.25% Triton X-100, and incubated with the antibody overnight
at 4°C. The primary antibodies used weremouse anti-Pax3 (R&D
Systems), rabbit anti-phospho CDC2-Y15, and rabbit anti-
phospho Histone H3 (Cell signaling Technology). After incu-
bation, the cells were washed with PBS and incubated with
fluorescein isothiocyanate-conjugated anti-mouse and anti-rabbit
IgG (Invitrogen) for 1 h. The cells were then examined by using
a Zeiss LSM700 confocal microscope and Zen 2010 imaging
software (Carl Zeiss).
Flow cytometry and cell cycle analysis
eYFP expression in mouse rhabdomyosarcoma cells and bone
marrow aspirates was assessed by flow cytometry. Cells were
stained with propidium iodide at 20 mg/mL for dead cell
elimination, followed by analysis on a FACScan cytometer
(Becton Dickinson). For cell cycle analysis, primary mouse
tumor cell cultures were harvested, washed with PBS, and fixed
in cold 70% ethanol for 20 min. After fixation, the cells were
washed with PBS and then incubated with RNase A and 20 mg/mL
propidium iodide. The cells were then analyzed by using an
Influx flow cytometer (Becton Dickinson) and FlowJo software
(Tree star, Inc.).
Western blotting
Procedures have been described previously (Abraham et al.
2011). The following primary antibodies were used: goat anti-
FKHR (catalog no. sc-9808, Santa Cruz Biotechnology) to de-
tect Pax3:Foxo1 and mouse anti-Noxa (catalog no. ab13654,
Abcam).
Drug sensitivity assays
Murine rhabdomyosarcoma primary tumor cell cultures were
plated in a 96-well plate at 2500 per well. After 24 h, the cells were
incubated with varying concentrations of entinostat (Selleckchem),
SAHA (LC Laboratories), and 5-Aza-29deoxycytidine (Sigma-
Aldrich) for 3 d. The cytotoxic effect of the drugs was then
assessed by using CellTiter 96 AQueous One cell proliferation
assay (MTS) and a BioTek Synergy 2 plate reader (BioTek).
Stable knockdown of Pax3:Foxo1
Murine primary tumor cell cultures with stable knockdown of
Pax3:Foxo1 were generated as described earlier (Kikuchi et al.
2014).
In vivo studies with entinostat
Orthotopic allograft mouse models of rhabdomyosarcoma were
generated as described earlier (Aslam et al. 2014). Once the
tumors reached 0.25 cm3, the mice were treated with either
entinostat (LC Laboratories) at a daily dose of 10 mg/kg by
intraperitoneal injection, actinomycin D (Sigma-Aldrich) at 0.25
mg/kg on day 1 by intraperitoneal injection, a combination of
entinostat and actinomycin D, or vehicle (DMSO). Once the
tumors reached 1.5 cm3 or the mice became sick (10%–15% loss
of body weight) due to drug toxicity, the mice were euthanized.
After 5 d of treatment with entinostat, the mice showed signs of
drug toxicity (loss of body weight), so the treatment was halted
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for a day and then continued with 5 mg/kg daily dose (half the
initial dose). All of the drug studies in mice were performed after
receiving approval from the IACUC at Oregon Health and
Science University.
Statistical analysis for in vivo studies with entinostat
A repeated measures linear mixed effects model with a com-
pound symmetric autocorrelation assumption to contrast treat-
ments pairwise on day 7 with regard to tumor size was used. Day
7 was chosen for analysis because this was the last day with
nearly complete data (actinomycin D, n = 7; actinomycin D +
entinostat, n = 8; DMSO, n = 7; entinostat, n = 9). The tumor size
data were log transformed prior to analysis and corrected the P-
values for multiple comparisons using the Tukey method.
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